Maria grew up in Berlin, Wisconsin. She started her career in journalism in Green Bay as the first CW 14 Star. She stepped away from TV while fighting breast cancer in 2020. With a great team of ...

Europe's largest pharmaceutical firm, Novo Nordisk, reported fourth-quarter earnings that surpassed analysts' expectations. The company’s shares jumped more than 6% at the market open in Europe ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs. Novo Nordisk said its fourth ...

While Novo’s type 2 diabetes GLP-1 Ozempic has largely stolen the show in recent years, obesity med Wegovy—which utilizes the same molecule semaglutide at higher doses than Ozempic ...

Financial giants have made a conspicuous bearish move on Novo Nordisk. Our analysis of options history for Novo Nordisk NVO revealed 18 unusual trades. Delving into the details, we found 33% of ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.

However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is ...

Danish drugmaker Novo Nordisk (NVO) reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's expectations and bumping its stock up more than 4% at market open.

A drug that Novo Nordisk acquired to expand its prospects in metabolic disorders has failed a mid-stage clinical trial in diabetic kidney disease. The results also showed signs of a ...

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its popular diabetes and weight loss medicines, including Wegovy and ...